^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)

    i
    Apply
    Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1) (NCT04224493)
    Phase 3
    Epizyme, Inc.
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    06/11/2020
    Primary completion :
    03/01/2026
    Completion :
    03/01/2029
    EZH2
    |
    EZH2 mutation
    |
    Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)
    A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (CELLO-1) (NCT04179864)
    Phase 1/2
    Epizyme, Inc.
    Active, not recruiting
    Last update posted :
    06/03/2024
    Initiation :
    11/18/2019
    Primary completion :
    06/28/2024
    Completion :
    06/28/2024
    EZH2
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tazverik (tazemetostat)
    A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation (Mandolin) (NCT06068881)
    Phase 2
    Epizyme, Inc.
    Not yet recruiting
    Last update posted :
    06/03/2024
    Initiation :
    09/02/2024
    Primary completion :
    09/28/2027
    Completion :
    09/28/2027
    EZH2
    |
    EZH2 mutation • EZH2 wild-type
    |
    Tazverik (tazemetostat)
    Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (ETCTN 10500) (NCT05627245)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/15/2024
    Initiation :
    03/01/2023
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    EZH2
    |
    RAS wild-type • EZH2 mutation • EZH2 wild-type
    |
    Tazverik (tazemetostat) • Beleodaq (belinostat)
    Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (NCT04659616)
    Phase 1
    OHSU Knight Cancer Institute
    Recruiting
    Last update posted :
    04/09/2024
    Initiation :
    01/14/2021
    Primary completion :
    08/01/2025
    Completion :
    02/01/2026
    TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2
    |
    TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation
    |
    cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)
    Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma (NCT05811546)
    Phase N/A
    Assiut University
    Recruiting
    Last update posted :
    04/13/2023
    Initiation :
    05/01/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    EZH2 • DNMT1
    PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia (NCT04215822)
    Phase N/A
    Assiut University
    Unknown status
    Last update posted :
    01/03/2020
    Initiation :
    01/01/2020
    Primary completion :
    01/30/2022
    Completion :
    04/01/2022
    EZH2
    |
    EZH2 deletion